KR20130108998A - 히드록시알킬 벤질 피라졸, 및 과다증식성 및 혈관신생 질환의 치료를 위한 그의 용도 - Google Patents
히드록시알킬 벤질 피라졸, 및 과다증식성 및 혈관신생 질환의 치료를 위한 그의 용도 Download PDFInfo
- Publication number
- KR20130108998A KR20130108998A KR1020127032070A KR20127032070A KR20130108998A KR 20130108998 A KR20130108998 A KR 20130108998A KR 1020127032070 A KR1020127032070 A KR 1020127032070A KR 20127032070 A KR20127032070 A KR 20127032070A KR 20130108998 A KR20130108998 A KR 20130108998A
- Authority
- KR
- South Korea
- Prior art keywords
- mmol
- methyl
- compound
- phenyl
- theory
- Prior art date
Links
- 0 Cc1cc(-c2nc(-c3cc(*)c(*)cc3)n[o]2)n[n]1Cc1cc(*O)ccc1 Chemical compound Cc1cc(-c2nc(-c3cc(*)c(*)cc3)n[o]2)n[n]1Cc1cc(*O)ccc1 0.000 description 13
- HFOQPLALJPQGBL-UHFFFAOYSA-N N/C(/c1ccc(C2(CCOCC2)F)cc1)=N\O Chemical compound N/C(/c1ccc(C2(CCOCC2)F)cc1)=N\O HFOQPLALJPQGBL-UHFFFAOYSA-N 0.000 description 2
- MILOMVVTWQDVHA-UHFFFAOYSA-N CC(C(F)(F)F)(c(c(F)c1)ccc1Br)O Chemical compound CC(C(F)(F)F)(c(c(F)c1)ccc1Br)O MILOMVVTWQDVHA-UHFFFAOYSA-N 0.000 description 1
- LCCQUAUGYNBEHE-UHFFFAOYSA-N CC(C)(C(F)(F)F)c(cc1)ccc1Br Chemical compound CC(C)(C(F)(F)F)c(cc1)ccc1Br LCCQUAUGYNBEHE-UHFFFAOYSA-N 0.000 description 1
- BQXOOCFUYAYYIT-UHFFFAOYSA-N CC(C)(COC(CN(C)C)=O)c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C(C)(C)C(F)(F)F)cc3)n[o]2)c1 Chemical compound CC(C)(COC(CN(C)C)=O)c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C(C)(C)C(F)(F)F)cc3)n[o]2)c1 BQXOOCFUYAYYIT-UHFFFAOYSA-N 0.000 description 1
- HGUJGDCREGQNHL-UHFFFAOYSA-N CC(C)(COP(O)(O)=O)c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C(C)(C)C(F)(F)F)cc3)n[o]2)c1 Chemical compound CC(C)(COP(O)(O)=O)c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C(C)(C)C(F)(F)F)cc3)n[o]2)c1 HGUJGDCREGQNHL-UHFFFAOYSA-N 0.000 description 1
- BBIKZBGVZCKOGT-UHFFFAOYSA-N CC(C)(Cc1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C4(COC)CCCC4)cc3)n[o]2)c1)O Chemical compound CC(C)(Cc1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C4(COC)CCCC4)cc3)n[o]2)c1)O BBIKZBGVZCKOGT-UHFFFAOYSA-N 0.000 description 1
- ZMGCZXCDJURMAJ-UHFFFAOYSA-N CC(C)(c(cc1)ccc1-c1n[o]c(-c2n[n](Cc3cc(C4(CC4)OC(C)=O)ccc3)c(C)c2)n1)F Chemical compound CC(C)(c(cc1)ccc1-c1n[o]c(-c2n[n](Cc3cc(C4(CC4)OC(C)=O)ccc3)c(C)c2)n1)F ZMGCZXCDJURMAJ-UHFFFAOYSA-N 0.000 description 1
- JPUQFWXSKJRAJF-UHFFFAOYSA-N CC(C)(c1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1)O Chemical compound CC(C)(c1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1)O JPUQFWXSKJRAJF-UHFFFAOYSA-N 0.000 description 1
- CKMOFJJDHSDKDE-UHFFFAOYSA-N CC(C)(c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C(C)(C)F)cc3)n[o]2)c1)O Chemical compound CC(C)(c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C(C)(C)F)cc3)n[o]2)c1)O CKMOFJJDHSDKDE-UHFFFAOYSA-N 0.000 description 1
- YXVDMVTWIPNSHS-UHFFFAOYSA-N CC(CO)(CO)c1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1 Chemical compound CC(CO)(CO)c1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1 YXVDMVTWIPNSHS-UHFFFAOYSA-N 0.000 description 1
- WUVXGCAWMQXSOC-UHFFFAOYSA-N CC(Cc1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1)O Chemical compound CC(Cc1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1)O WUVXGCAWMQXSOC-UHFFFAOYSA-N 0.000 description 1
- FPBNPUVUSFZNDZ-UHFFFAOYSA-N CC(OC1(CC1)c1cc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3S(F)(F)(F)(F)F)n[o]2)ccc1)=O Chemical compound CC(OC1(CC1)c1cc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3S(F)(F)(F)(F)F)n[o]2)ccc1)=O FPBNPUVUSFZNDZ-UHFFFAOYSA-N 0.000 description 1
- ABOIEDGKYVOIOS-UHFFFAOYSA-N CC(OC1(CC1)c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C4CCCCC4)cc3)n[o]2)c1)=O Chemical compound CC(OC1(CC1)c1cccc(C[n](c(C)c2)nc2-c2nc(-c3ccc(C4CCCCC4)cc3)n[o]2)c1)=O ABOIEDGKYVOIOS-UHFFFAOYSA-N 0.000 description 1
- BZWWJGWXOQSURW-UHFFFAOYSA-N CCOC(Cc1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1)=O Chemical compound CCOC(Cc1cccc(C[n](c(C)c2)nc2-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)c1)=O BZWWJGWXOQSURW-UHFFFAOYSA-N 0.000 description 1
- LHJUCXURYQECJP-UHFFFAOYSA-N CCOCC1(CCC1)c(cc1)ccc1/C(/N)=N/O Chemical compound CCOCC1(CCC1)c(cc1)ccc1/C(/N)=N/O LHJUCXURYQECJP-UHFFFAOYSA-N 0.000 description 1
- RBZRGLAWSOPQJA-UHFFFAOYSA-N COCC1(CCC1)c(c(F)c1)ccc1/C(/N)=N/O Chemical compound COCC1(CCC1)c(c(F)c1)ccc1/C(/N)=N/O RBZRGLAWSOPQJA-UHFFFAOYSA-N 0.000 description 1
- YBIYVYUIYNVUEJ-UHFFFAOYSA-N COCC1(CCCC1)c(cc1)ccc1Br Chemical compound COCC1(CCCC1)c(cc1)ccc1Br YBIYVYUIYNVUEJ-UHFFFAOYSA-N 0.000 description 1
- VHLIEEMRGVWHLK-UHFFFAOYSA-N Cc1cc(-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)n[n]1Cc1cc(C2(CCC2)O)ccc1 Chemical compound Cc1cc(-c2nc(-c(cc3)ccc3OC(F)(F)F)n[o]2)n[n]1Cc1cc(C2(CCC2)O)ccc1 VHLIEEMRGVWHLK-UHFFFAOYSA-N 0.000 description 1
- ZIYMIFPGHOJDIN-UHFFFAOYSA-N Cc1cc(-c2nc(-c3ccc(C4(CCC4)F)cc3)n[o]2)n[n]1Cc1cc(C(OC)=O)ccc1 Chemical compound Cc1cc(-c2nc(-c3ccc(C4(CCC4)F)cc3)n[o]2)n[n]1Cc1cc(C(OC)=O)ccc1 ZIYMIFPGHOJDIN-UHFFFAOYSA-N 0.000 description 1
- YZNWNSRWCIHSKY-UHFFFAOYSA-N Cc1cc(-c2nc(-c3ccc(C4(COC4)F)cc3)n[o]2)n[n]1Cc1cc(C(CO)(F)F)ccc1 Chemical compound Cc1cc(-c2nc(-c3ccc(C4(COC4)F)cc3)n[o]2)n[n]1Cc1cc(C(CO)(F)F)ccc1 YZNWNSRWCIHSKY-UHFFFAOYSA-N 0.000 description 1
- RUALYGQMSSBATI-UHFFFAOYSA-N Cc1cc(/C(/N)=N/O)ccc1OC(F)(F)F Chemical compound Cc1cc(/C(/N)=N/O)ccc1OC(F)(F)F RUALYGQMSSBATI-UHFFFAOYSA-N 0.000 description 1
- UPIVJZKUPXXOJE-UHFFFAOYSA-N Cc1cccc(C(CO)(F)F)c1 Chemical compound Cc1cccc(C(CO)(F)F)c1 UPIVJZKUPXXOJE-UHFFFAOYSA-N 0.000 description 1
- XRLHAJCIEMOBLT-UHFFFAOYSA-N NC1(CCC1)N Chemical compound NC1(CCC1)N XRLHAJCIEMOBLT-UHFFFAOYSA-N 0.000 description 1
- KFDKGQUNVQANPL-UHFFFAOYSA-N OCC(c1cc(CBr)ccc1)(F)F Chemical compound OCC(c1cc(CBr)ccc1)(F)F KFDKGQUNVQANPL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10004854.5 | 2010-05-08 | ||
| EP10004854 | 2010-05-08 | ||
| PCT/EP2011/057019 WO2011141325A1 (de) | 2010-05-08 | 2011-05-03 | Hydroxyalkylbenzyl- pyrazole und ihre verwendung zur behandlung von hyperproliferativen und angiogenen erkrankungen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20130108998A true KR20130108998A (ko) | 2013-10-07 |
Family
ID=44243203
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020127032070A KR20130108998A (ko) | 2010-05-08 | 2011-05-03 | 히드록시알킬 벤질 피라졸, 및 과다증식성 및 혈관신생 질환의 치료를 위한 그의 용도 |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2569309A1 (de) |
| JP (1) | JP2013530139A (de) |
| KR (1) | KR20130108998A (de) |
| CN (1) | CN103003266A (de) |
| AU (1) | AU2011252222A1 (de) |
| BR (1) | BR112012028652A2 (de) |
| CA (1) | CA2798374A1 (de) |
| IL (1) | IL222850A0 (de) |
| MX (1) | MX2012012905A (de) |
| RU (1) | RU2012152800A (de) |
| WO (1) | WO2011141325A1 (de) |
| ZA (1) | ZA201209298B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014031928A2 (en) * | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| US9018380B2 (en) | 2012-08-24 | 2015-04-28 | Boar of Regents, The University of Texas System | Heterocyclic modulators of HIF activity for treatment of disease |
| WO2014031933A2 (en) | 2012-08-24 | 2014-02-27 | Philip Jones | Heterocyclic modulators of hif activity for treatment of disease |
| ES2726648T3 (es) | 2014-02-25 | 2019-10-08 | Univ Texas | Sales de moduladores heterocíclicos de la actividad del HIF para el tratamiento de enfermedades |
| CN107235873B (zh) * | 2017-07-04 | 2018-11-06 | 中节能万润股份有限公司 | 一种美司钠的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060194807A1 (en) | 2003-04-03 | 2006-08-31 | Cosford Nicholas D P | Di-aryl substituted pyrazole modulators of metabotropic glutamate receptor-5 |
| AU2004275694B2 (en) | 2003-06-30 | 2008-03-06 | Bizbiotech Co., Ltd. | Compounds, compositions and methods |
| WO2007065010A2 (en) | 2005-12-02 | 2007-06-07 | Hif Bio, Inc. | Anti-angiogenesis compounds |
| CN101765596B (zh) | 2007-05-18 | 2015-04-29 | 拜耳知识产权有限责任公司 | 用于治疗过增生症状和与血管生成有关疾病的缺氧诱导因子(hif)抑制剂 |
| DE102008057344A1 (de) * | 2008-11-14 | 2010-05-20 | Bayer Schering Pharma Aktiengesellschaft | Aminoalkyl-substituierte Aryl-Verbindungen und ihre Verwendung |
| PL2356113T3 (pl) * | 2008-11-14 | 2015-06-30 | Bayer Ip Gmbh | Heterocyklicznie podstawione związki arylowe jako inhibitory HIF |
| EP2202232A1 (de) | 2008-12-26 | 2010-06-30 | Laboratorios Almirall, S.A. | 1,2,4 Oxadiazolderivate und ihr Einsatz als Arzneimittel |
| EP2382211B1 (de) | 2009-01-23 | 2012-12-19 | Bristol-Myers Squibb Company | Pyrazol-1,2,4-oxadiazolderivate als sphingosin-1-phosphatagonisten |
-
2011
- 2011-05-03 MX MX2012012905A patent/MX2012012905A/es unknown
- 2011-05-03 AU AU2011252222A patent/AU2011252222A1/en not_active Abandoned
- 2011-05-03 CN CN2011800338366A patent/CN103003266A/zh active Pending
- 2011-05-03 WO PCT/EP2011/057019 patent/WO2011141325A1/de active Application Filing
- 2011-05-03 EP EP11716947A patent/EP2569309A1/de not_active Withdrawn
- 2011-05-03 JP JP2013509504A patent/JP2013530139A/ja not_active Withdrawn
- 2011-05-03 RU RU2012152800/04A patent/RU2012152800A/ru not_active Application Discontinuation
- 2011-05-03 KR KR1020127032070A patent/KR20130108998A/ko not_active Application Discontinuation
- 2011-05-03 CA CA2798374A patent/CA2798374A1/en not_active Abandoned
- 2011-05-03 BR BR112012028652A patent/BR112012028652A2/pt not_active IP Right Cessation
-
2012
- 2012-11-05 IL IL222850A patent/IL222850A0/en unknown
- 2012-12-07 ZA ZA2012/09298A patent/ZA201209298B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013530139A (ja) | 2013-07-25 |
| IL222850A0 (en) | 2012-12-31 |
| RU2012152800A (ru) | 2014-06-20 |
| CA2798374A1 (en) | 2011-11-17 |
| AU2011252222A1 (en) | 2012-12-06 |
| ZA201209298B (en) | 2014-05-28 |
| CN103003266A (zh) | 2013-03-27 |
| EP2569309A1 (de) | 2013-03-20 |
| MX2012012905A (es) | 2012-12-17 |
| BR112012028652A2 (pt) | 2016-08-09 |
| WO2011141325A1 (de) | 2011-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20130108997A (ko) | 치환된 헤테로시클릴 벤질 피라졸 및 그의 용도 | |
| JP5829915B2 (ja) | 複素環式置換基を有するアリール化合物およびそれらの使用 | |
| US20130150325A1 (en) | 3-(Fluorovinyl)pyrazoles and their use | |
| US20140329797A1 (en) | Substituted oxadiazolyl pyridinones and oxadiazolyl pyridazinones as hif inhibitors | |
| JP2020506946A (ja) | がん治療のための２−ヘテロアリール−３−オキソ−２，３−ジヒドロピリダジン−４−カルボキサミド類 | |
| KR20110082570A (ko) | Ｈｉｆ 억제제로서 사용하기 위한 헤테로방향족 화합물 | |
| JP2012508702A (ja) | アミノアルキル置換基を有するアリール化合物およびそれらの使用 | |
| AU2010294588A1 (en) | Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs | |
| JP2021521128A (ja) | 二環式カルボキサミドおよびその使用方法 | |
| KR20130108998A (ko) | 히드록시알킬 벤질 피라졸, 및 과다증식성 및 혈관신생 질환의 치료를 위한 그의 용도 | |
| DE102008057364A1 (de) | Substituierte Aryl-Verbindungen und ihre Verwendung | |
| TW201311646A (zh) | ３－（氟乙烯基）吡唑類及其用途 | |
| DE102009041241A1 (de) | Substituierte Aryl-Verbindungen und ihre Verwendung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |